Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback